Wednesday - November 5, 2025
GSK: Blenrep Approved by U.S. FDA for Use in Treatment of Relapsed/refractory Multiple Myeloma
October 24, 2025
LONDON, England, Oct. 24 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Oct. 23, 2025:

* * *

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

* Significant unmet need for patients requires new and novel treatments/1

* DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a da . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products